In contrast, the study of Carmona et al. reported no alterations in AKT2 among HER2-positive breast cancers, but they found alterations of AKT3 in 10% of HER2 breast cancer (mostly amplifications) and alterations of AKT1 in 2.5% (mostly E17K mutations) [202]. Here, ERBB2 is linked to breast carcinoma.